The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
441 - There is a unique provincial situation in which the manufacturer has lowered the price of its drug to match the price of its generic substitute. Can we create an APS that speaks to this fact and claim that patients can continue to receive said drug "at no additional cost* compared to the generic version."? *Refers to the drug acquisition cost; dispensing fees not covered.
Claims & Support/References for Claims
1
Posts
1
Posters
281
Views
1
Watching
-
A Q&A forum is not the optimal forum for this type of question as it requires a review. I will not speak to your particular case (as I don’t know the details). I will say that a message such as “at no additional cost” suggests that no patient ever needs to pay more than they would for the generic alternative. This claim is misleading unless it is unequivocally true.
